Inhibrx, Inc. (INBX)
- Previous Close
34.39 - Open
34.10 - Bid 34.42 x 200
- Ask 34.50 x 100
- Day's Range
34.10 - 34.48 - 52 Week Range
14.31 - 39.79 - Volume
301,548 - Avg. Volume
453,826 - Market Cap (intraday)
1.632B - Beta (5Y Monthly) 2.91
- PE Ratio (TTM)
-- - EPS (TTM)
-5.12 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.50
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
inhibrx.comRecent News: INBX
Performance Overview: INBX
Trailing total returns as of 5/8/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INBX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INBX
Valuation Measures
Market Cap
1.63B
Enterprise Value
1.56B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
899.40
Price/Book (mrq)
37.42
Enterprise Value/Revenue
866.75
Enterprise Value/EBITDA
-7.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.77%
Return on Equity (ttm)
-475.31%
Revenue (ttm)
1.8M
Net Income Avi to Common (ttm)
-241.36M
Diluted EPS (ttm)
-5.12
Balance Sheet and Cash Flow
Total Cash (mrq)
277.92M
Total Debt/Equity (mrq)
483.05%
Levered Free Cash Flow (ttm)
-112.84M
Research Analysis: INBX
Company Insights: INBX
INBX does not have Company Insights